Business Context and Reporting Period
This Form 8-K Current Report was filed by Immunocore Holdings Plc on August 28, 2024. The filing discloses a significant corporate governance event regarding the departure of a senior executive.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a disclosure of personnel changes.
Material Changes
The primary material change reported is the resignation of Mr. Brian Di Donato, who served as Executive Vice President, Chief Financial Officer, Head of Strategy, and principal financial officer. His resignation is effective December 31, 2024. The Company has initiated a formal search for his replacement.
Management Commentary and Risks
- Reason for Departure: Mr. Di Donato is resigning to pursue another opportunity.
- Disagreement Status: The filing explicitly states the resignation was not due to any disagreement with the Company regarding financial statements, internal controls, operations, policies, or accounting practices.
- Regulatory Disclosure: A press release announcing the departure is included as Exhibit 99.1 under Regulation FD.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Review the press release (Exhibit 99.1) for additional context on the transition plan.
- Monitor upcoming quarterly reports for any impact on financial reporting continuity during the interim period.